Inclusion Criteria:
- Must have diagnosis of atopic dermatitis (AD) at least 12 months prior to screening
- Documented history of inadequate response to treatment with topical medication for at
least 4 weeks, unless topical treatments are otherwise medically inadvisable, or has
required systemic therapy for control of disease
- All the following must be present to confirm moderate-to-severe AD
- Eczema Area and Severity Index score ≥ 12 (at Screening and Day 1)
- Body Surface Area ≥ 10% (at Screening and Day 1)
- Validated Investigator Global Assessment for Atopic Dermatitis ≥ 3 (at Screening
and Day 1)
- Peak Pruritus Numerical Rating Scale ≥ 4 (at Screening)
Exclusion Criteria:
- Evidence of an active and/or concurrent inflammatory skin condition that would
interfere with the Investigator or subject-driven evaluations of AD
- Any major surgery within the last 30 days before the first dose of study intervention,
or any surgery planned during the course of the study
- Any other sound medical, psychiatric, and/or social reason as determined by the
investigator
Other protocol-defined inclusion/exclusion criteria apply
